Biocon Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on December 31, 2025. Further, the company has informed the Exchange regarding voting results.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited held an Extraordinary General Meeting on December 31, 2025, via video conferencing, where all six resolutions were passed with the requisite majority. Key items included an increase in authorised share capital, expansion of investment/loan limits under Section 186, preferential allotment of equity shares (where promoters were interested), raising of funds through equity/other securities, granting of special rights to investors, and approval of material related party transactions with Mylan Inc. (where promoters abstained). Voting participation was high at around 81% of outstanding shares. Notably, Resolution 2 (increase in investment limits under Section 186) saw significant dissent, with nearly 15.67% of votes polled (about 16.94 crore shares) voting against it, while all other resolutions passed with over 99% support.
All resolutions were approved, enabling Biocon to expand its authorised share capital, raise fresh capital, issue shares on a preferential basis, and proceed with related party transactions with Mylan Inc. However, the meaningful opposition to the Section 186 investment limits resolution (~16% dissent) may signal some shareholder concern about expanded borrowing/investment flexibility. Shareholders should watch for the company's subsequent announcement detailing the actual fundraise size and pricing.